Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. is leveraging its unique resources from the Changbai Mountain region to enhance its competitiveness in the traditional Chinese medicine industry, with a projected net profit growth of 130% to 140% year-on-year for the first half of the year [1] Group 1: Resource Utilization and Quality Control - The company has established the largest GAP-certified deer farm in Asia and a medicinal herb base in Changbai Mountain, ensuring the quality and stable supply of medicinal materials [2] - Jilin Aodong has built a standardized and large-scale medicinal herb planting base and employs a gene identification system for medicinal herbs, enhancing product innovation and quality control [2][3] - The company has developed a comprehensive database for northern medicinal herbs, addressing key challenges in seed breeding and standardized planting [3] Group 2: Innovation in Production and Technology - Jilin Aodong is focusing on modernizing traditional Chinese medicine through the development of granule formulations, which are seen as a key competitive advantage [4] - The company has invested 1 billion yuan in a granule formulation project, which will have an extraction capacity of 5,000 tons annually and is set to begin operations by the end of 2024 [4] - The extraction process has been fully automated, ensuring precise control over various parameters and enhancing product traceability and optimization [5] Group 3: Research and Development - The company has conducted over 5,000 studies on the processes and testing of granule formulations, successfully applying dynamic extraction and low-temperature concentration techniques [6] - Jilin Aodong has developed 525 varieties of granule formulations, including over 20 types of local medicinal materials from Jilin Province [6] Group 4: Talent Development and Financial Strategy - The company is building a diverse team of innovative talents and has established various national and local standards for the industry [7] - Jilin Aodong is enhancing its development model through a multi-wheel drive strategy that integrates medicine, finance, and health, with financial capital playing a crucial role [7] - The company aims to redefine the modernization path of the traditional Chinese medicine industry by integrating financial resources and digital technology to drive growth [7]